Imugene Ltd (ASX:IMU, OTC:IUGNF) has appointed two-decade veteran Dr Ron Weitzman as its interim chief medical officer, replacing Dr Giovanni Selvaggi.
Dr Weitzman brings extensive global experience to the company, along with his expertise in the therapeutic areas of solid tumour and hematologic malignancies.
IMU will draw on his extensive record in creating and executing clinical development plans, directing Phase I - III clinical trials, and preparing US and EU regulatory submissions.
"It’s a pleasure to welcome Dr Weitzman to our leadership team," Imugene managing director and CEO Leslie Chong said.
"His wealth of experience in drug development will prove invaluable as we continue to advance our pipeline.
"His strong regulatory and oncology drug development background and demonstrated success in overseeing complex projects will also be an excellent asset that will complement our already world-class team."
About Dr Weitzman
Dr Weitzman has held leadership roles at various global biopharmaceutical companies, including Tango Therapeutics, Exelixis, Genentech and Novartis.
His most recent position was as chief medical officer at Tango Therapeutics, where he oversaw development of multiple oncology drugs, including three Investigational New Drug (IND) submissions, while leading the clinical and clinical operations teams.
Prior to Tango, Dr Weitzman served as vice president of Clinical Development at Exelixis for almost seven years, where he had overall responsibility for the strategy and execution of the clinical plan for cabozantinib, a drug therapy for prostate cancer.
Importantly for IMU, this role included numerous visits to FDA and EMEA, authorship of regulatory documents, active participation in industry partnership meetings, and presentations to investors and the Exelixis Board of Directors.
Dr Weitzman is board-certified by the American Board of Internal Medicine in Medical Oncology and is an active member of several professional societies including the College of Physicians and Surgeons of Ontario, the American College of Physicians, and the American Society of Clinical Oncology.